Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
Purpose: To report the visual and anatomical outcomes of intravitreal ziv-aflibercept (IVZ) and bevacizumab (BVZ) monotherapy in treatment-naive polypoidal choroidal vasculopathy (PCV). Methods: This was a retrospective case series of 16 eyes (8 eyes each in IVZ and BVZ groups). The study period was...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
Series: | Indian Journal of Ophthalmology |
Subjects: | |
Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=7;spage=1114;epage=1118;aulast=Singh |
id |
doaj-e1cbb80982c747ae89c4c2f70ec01983 |
---|---|
record_format |
Article |
spelling |
doaj-e1cbb80982c747ae89c4c2f70ec019832020-11-24T21:52:49ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892019-01-016771114111810.4103/ijo.IJO_638_18Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathySumit Randhir SinghNiroj Kumar SahooNallamasa Rohit GoudJay ChhablaniPurpose: To report the visual and anatomical outcomes of intravitreal ziv-aflibercept (IVZ) and bevacizumab (BVZ) monotherapy in treatment-naive polypoidal choroidal vasculopathy (PCV). Methods: This was a retrospective case series of 16 eyes (8 eyes each in IVZ and BVZ groups). The study period was from January 2016 to March 2018. The inclusion criteria were treatment-naive PCV patients who were treated with either IVZ or BVZ monotherapy on pro re nata protocol and followed up monthly for 6 months. The change in best-corrected visual acuity (BCVA), central macular thickness (CMT), and pigment epithelial detachment (PED) height was measured at baseline and 6 months. Results: A total of 16 eyes were studied. IVZ group had an improvement in BCVA by 0.15 logarithm of minimum angle of resolution (logMAR; approximately 1.5 lines) at 6 months, whereas BVZ group had a reduction in BCVA by 0.21 logMAR (approximately 2 lines) (P = 0.027). Five patients and one patient in IVZ and BVZ groups, respectively, had ≥5 letters gain of BCVA. IVZ group had significant reduction in PED height (P = 0.048), whereas the change in CMT was not significant at 6 months (P = 0.681). The mean number of injections (2.87 ± 0.83 in IVZ and 2.25 ± 0.89 BVZ group; P = 0.168) and longest treatment-free interval (3.00 ± 2.20 months in IVZ and 2.12 ± 1.96 months in BVZ group; P = 0.41) were not significantly different. Conclusion: The visual and anatomical outcomes in terms of PED reduction in treatment-naive PCV patients were better in IVZ group compared with BVZ. IVZ monotherapy is a viable, cost-effective alternative in these patients with good safety profile.http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=7;spage=1114;epage=1118;aulast=SinghIntravitreal bevacizumabintravitreal ziv-afliberceptpolypoidal choroidal vasculopathy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sumit Randhir Singh Niroj Kumar Sahoo Nallamasa Rohit Goud Jay Chhablani |
spellingShingle |
Sumit Randhir Singh Niroj Kumar Sahoo Nallamasa Rohit Goud Jay Chhablani Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy Indian Journal of Ophthalmology Intravitreal bevacizumab intravitreal ziv-aflibercept polypoidal choroidal vasculopathy |
author_facet |
Sumit Randhir Singh Niroj Kumar Sahoo Nallamasa Rohit Goud Jay Chhablani |
author_sort |
Sumit Randhir Singh |
title |
Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy |
title_short |
Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy |
title_full |
Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy |
title_fullStr |
Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy |
title_full_unstemmed |
Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy |
title_sort |
comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy |
publisher |
Wolters Kluwer Medknow Publications |
series |
Indian Journal of Ophthalmology |
issn |
0301-4738 1998-3689 |
publishDate |
2019-01-01 |
description |
Purpose: To report the visual and anatomical outcomes of intravitreal ziv-aflibercept (IVZ) and bevacizumab (BVZ) monotherapy in treatment-naive polypoidal choroidal vasculopathy (PCV). Methods: This was a retrospective case series of 16 eyes (8 eyes each in IVZ and BVZ groups). The study period was from January 2016 to March 2018. The inclusion criteria were treatment-naive PCV patients who were treated with either IVZ or BVZ monotherapy on pro re nata protocol and followed up monthly for 6 months. The change in best-corrected visual acuity (BCVA), central macular thickness (CMT), and pigment epithelial detachment (PED) height was measured at baseline and 6 months. Results: A total of 16 eyes were studied. IVZ group had an improvement in BCVA by 0.15 logarithm of minimum angle of resolution (logMAR; approximately 1.5 lines) at 6 months, whereas BVZ group had a reduction in BCVA by 0.21 logMAR (approximately 2 lines) (P = 0.027). Five patients and one patient in IVZ and BVZ groups, respectively, had ≥5 letters gain of BCVA. IVZ group had significant reduction in PED height (P = 0.048), whereas the change in CMT was not significant at 6 months (P = 0.681). The mean number of injections (2.87 ± 0.83 in IVZ and 2.25 ± 0.89 BVZ group; P = 0.168) and longest treatment-free interval (3.00 ± 2.20 months in IVZ and 2.12 ± 1.96 months in BVZ group; P = 0.41) were not significantly different. Conclusion: The visual and anatomical outcomes in terms of PED reduction in treatment-naive PCV patients were better in IVZ group compared with BVZ. IVZ monotherapy is a viable, cost-effective alternative in these patients with good safety profile. |
topic |
Intravitreal bevacizumab intravitreal ziv-aflibercept polypoidal choroidal vasculopathy |
url |
http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=7;spage=1114;epage=1118;aulast=Singh |
work_keys_str_mv |
AT sumitrandhirsingh comparisonofintravitrealzivafliberceptandbevacizumabmonotherapyintreatmentnaivepolypoidalchoroidalvasculopathy AT nirojkumarsahoo comparisonofintravitrealzivafliberceptandbevacizumabmonotherapyintreatmentnaivepolypoidalchoroidalvasculopathy AT nallamasarohitgoud comparisonofintravitrealzivafliberceptandbevacizumabmonotherapyintreatmentnaivepolypoidalchoroidalvasculopathy AT jaychhablani comparisonofintravitrealzivafliberceptandbevacizumabmonotherapyintreatmentnaivepolypoidalchoroidalvasculopathy |
_version_ |
1725874668190040064 |